What Is Zepbound?
Zepbound is the brand name for tirzepatide, a medication that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
GLP-1 is a naturally occurring hormone involved in appetite, satiety, glucose regulation, and digestion. These medications do more than simply make patients "feel less hungry." They alter appetite, satiety, food reward, cravings, and metabolic regulation in ways that make maintaining a lower energy intake substantially easier. However, increased energy expenditure does not appear to be a major mechanism of current GLP-1–based medications.
Zepbound is administered as a once-weekly injection.
How Is Zepbound Different From Wegovy?
Zepbound and Wegovy are both used for medical weight management, but they differ in mechanism, formulation, clinical evidence, and FDA-approved indications.
- Dual GIP + GLP-1 Action: Tirzepatide (Zepbound) is a dual peptide medication and acts on both GIP and GLP-1 receptors. Semaglutide (Wegovy) acts on the GLP-1 receptor alone.
- Greater Average Weight Loss in a Direct Comparison: In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks.
- Obstructive Sleep Apnea: Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Is Zepbound the Same as Mounjaro?
Zepbound and Mounjaro contain the same active medication - tirzepatide - but they are FDA-approved for different indications.
Mounjaro is used to treat type 2 diabetes. Zepbound is approved for chronic weight management in appropriate patients with overweight or obesity and for moderate-to-severe obstructive sleep apnea in adults with obesity.
The underlying medication is the same, but the available doses and dosing schedules differ between the two commercial products.
How Much Weight Can You Lose With Zepbound?
Individual response varies, but tirzepatide has produced substantial weight loss in clinical trials.
In the original SURMOUNT-1 trial, adults with obesity or overweight without diabetes lost an average of approximately 15% to 21% of their starting body weight over 72 weeks, depending on dose.
Longer-term research in participants with obesity and prediabetes demonstrated sustained weight reduction over three years of treatment.
Some men lose considerably more or less than these averages. Treatment response, tolerability, body composition, metabolic health, and the sustainability of the strategy are all important considerations.
Zepbound, Visceral Fat, and Men's Metabolic Health
For men, where excess fat is stored matters.
Men tend to accumulate more visceral fat - the deeper abdominal fat surrounding internal organs - which is strongly associated with insulin resistance, cardiovascular disease, abnormal cholesterol, metabolic liver disease, and other cardiometabolic risks.
Tirzepatide has been shown to substantially reduce waist circumference, an important clinical marker of abdominal adiposity. In the direct SURMOUNT-5 comparison, average waist circumference decreased by 18.4 cm with tirzepatide over 72 weeks.
Reducing excess abdominal and visceral fat can improve insulin sensitivity and other cardiometabolic risk factors.
The goal is better body composition - not simply lower body weight.
Zepbound and Prediabetes
Tirzepatide has also been studied over several years in people with obesity and prediabetes.
In a three-year analysis of SURMOUNT-1, participants receiving tirzepatide experienced sustained weight loss and were substantially less likely to progress from prediabetes to type 2 diabetes than participants receiving placebo.
These findings are particularly relevant for men with insulin resistance, elevated glucose, excess visceral fat, or other signs of metabolic dysfunction.
Zepbound and Obstructive Sleep Apnea
Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, in conjunction with a reduced-calorie diet and increased physical activity.
In clinical trials, tirzepatide reduced the frequency of breathing interruptions during sleep and also reduced body weight.
Sleep apnea is particularly relevant to men's health because it is associated with metabolic and cardiovascular disease and may also affect energy, sleep quality, and hormonal health.
Weight Loss Shouldn't Mean Losing Muscle
Significant weight loss can involve loss of both fat and lean tissue. Preserving skeletal muscle is particularly important for men in midlife and beyond.
Our approach emphasizes adequate protein intake, resistance training, appropriate nutrition, and thoughtful medication dosing to support muscle preservation while reducing excess fat.
The goal is better body composition - not simply lower body weight.
Zepbound, Weight Loss, and Testosterone
Excess visceral fat and metabolic dysfunction can contribute to lower testosterone in some men. Conversely, clinically significant testosterone deficiency can contribute to reduced muscle mass and changes in body composition.
Zepbound is not a treatment for low testosterone, and testosterone therapy is not a weight-loss treatment. When symptoms or clinical history warrant it, testosterone evaluation can be considered alongside the broader metabolic assessment.
Learn More About Testosterone Evaluation
Learn More About Testosterone Evaluation
What Can I Expect When Taking Zepbound?
The experience varies from person to person.
Many men notice less hunger, earlier fullness, smaller portions, and less interest in food as the dose is gradually increased. Men often report less "food noise."
Nausea, diarrhea or constipation, vomiting, abdominal discomfort, or reflux can occur. However, many of these side effects can be mitigated or avoided through "low and slow" dosing i.e., gradual titration based on response and tolerability.
Zepbound Side Effects and Safety
The most common side effects of Zepbound are gastrointestinal and may include:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Abdominal discomfort
- Indigestion or acid reflux (GERD)
More significant adverse effects can occur and should be reviewed before treatment.
Zepbound carries a boxed warning regarding thyroid C-cell tumors observed in animal studies and should not be used in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). GLP-1s have also been associated with increased risks of pancreatitis, gallbladder problems, kidney injury from dehydration, gastrointestinal effects including gastroparesis
Who Is a Candidate for Zepbound?
Zepbound is approved for long-term weight management in adults with obesity, or adults with overweight plus at least one weight-related health condition, when appropriate.
Men often seek treatment because of increasing abdominal or visceral fat, worsening metabolic markers, prediabetes, sleep apnea, repeated weight regain, or weight that has become increasingly difficult to manage.
Eligibility for a medication and the decision to use it are not necessarily the same thing.
We also consider:
- Metabolic risk
- Cardiovascular disease or disease risk
- Prediabetes or insulin resistance
- Sleep apnea
- Weight history and previous treatment
- Medical history and contraindications
- Treatment goals and patient preference
For some men, another medication - or a strategy that does not involve medication - may be more appropriate.
How Is Zepbound Dosed and Monitored?
Zepbound is typically started at a low dose and increased gradually as the body adjusts. Commercial Zepbound pens use fixed-dose increments, but when clinically appropriate, other prescribed vial formulations may allow smaller, intermediate dose adjustments and a more gradual titration based on individual response and tolerability.
At Performance Men's Health, the goal is not simply to increase the dose as quickly as possible. We monitor appetite, weight trajectory, side effects, metabolic markers, and changes in body composition. We do not routinely aim for the maximum dose. Many patients can achieve meaningful weight loss at lower doses.
Protein intake, resistance training, sleep, and other factors that support muscle preservation and long-term metabolic health are addressed throughout treatment.
START LOW → TITRATE INDIVIDUALLY → MONITOR RESPONSE → PRESERVE MUSCLE → PLAN FOR MAINTENANCE
What Happens If You Stop Zepbound?
Weight regain after stopping tirzepatide is common because the biological signals involved in hunger and weight regulation can return when medication is discontinued.
That does not mean every patient must remain on the same medication or dose indefinitely. Long-term strategies may include continued therapy, individualized dosing, transitioning treatment, or carefully monitored discontinuation.
Planning for weight maintenance should begin before goal weight is reached.
Zepbound vs. Wegovy: A Closer Comparison
|
ZEPBOUND® |
WEGOVY® |
| Active medication |
Tirzepatide |
Semaglutide |
| Mechanism |
GIP + GLP-1 |
GLP-1 |
| Formulation |
Once-weekly injection |
Injection or oral tablet |
| Head-to-head average weight loss* |
20.20% |
13.70% |
| Additional FDA indication highlighted here |
Moderate-to-severe OSA in adults with obesity |
Cardiovascular risk reduction in certain adults with established CVD and overweight or obesity |
*SURMOUNT-5 was a head to head trial that compared maximum tolerated doses of injectable semaglutide and tirzepatide over 72 weeks in adults with obesity without diabetes. In this trial, patients lost an average of 13.7% of their body weight.
Zepbound at Performance Men's Health
Zepbound can be a highly effective weight loss treatment for appropriate men, but medication is only one component of weight management.
Our approach considers visceral fat, muscle mass, metabolic health, nutrition, exercise, medication response, testosterone screening, and long-term maintenance strategies.